Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Schizophrenia Research and Treatment |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.hindawi.com/journals/sprt/2012/764769/ |
| Doi | http://dx.doi.org/10.1155/2012/764769 |
| Field | Psychiatry, sexuology |
| Keywords | first episode schizophrenia; injectable; second generation antipsychotics; |
| Attached files | |
| Description | Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone) in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life. |
| Related projects: |